{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,9,30]],"date-time":"2024-09-30T06:10:10Z","timestamp":1727676610723},"reference-count":72,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T00:00:00Z","timestamp":1759104000000},"content-version":"am","delay-in-days":363,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Revue des Maladies Respiratoires"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1016\/j.rmr.2024.05.004","type":"journal-article","created":{"date-parts":[[2024,6,25]],"date-time":"2024-06-25T11:36:38Z","timestamp":1719315398000},"page":"571-582","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["CBNPC sans addictions oncog\u00e9niques m\u00e9tastatique c\u00e9r\u00e9bral d\u2019embl\u00e9e\u00a0: place de l\u2019immunoth\u00e9rapie"],"prefix":"10.1016","volume":"41","author":[{"given":"B.","family":"Nigen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"Bodergat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Vaugier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Pons-Tostivint","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.rmr.2024.05.004_bib0005","unstructured":"Masson E. EM-Consulte [cited 2022\u00a0April 24]. M\u00e9tastases c\u00e9r\u00e9brales et leptom\u00e9ning\u00e9es des cancers solides. Available from: https:\/\/www.em-consulte.com\/article\/2547\/metastases-cerebrales-et-leptomeningees-des-cancer."},{"key":"10.1016\/j.rmr.2024.05.004_bib0010","first-page":"4655","article-title":"Recent trends in epidemiology of brain metastases: an overview","volume":"32","author":"Tabouret","year":"2012","journal-title":"Anticancer Res"},{"key":"10.1016\/j.rmr.2024.05.004_bib0015","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1038\/s41572-018-0055-y","article-title":"Brain metastases","volume":"5","author":"Achrol","year":"2019","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.rmr.2024.05.004_bib0020","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1007\/s11060-017-2574-x","article-title":"Negative impact of leukoaraiosis on the incidence of brain metastases in patients with lung cancer","volume":"135","author":"Hayashi","year":"2017","journal-title":"J Neurooncol"},{"key":"10.1016\/j.rmr.2024.05.004_bib0025","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.lungcan.2004.01.025","article-title":"Multivariate analysis of factors predictive of brain metastases in localised non-small cell lung carcinoma","volume":"45","author":"Bajard","year":"2004","journal-title":"Lung Cancer"},{"issue":"12","key":"10.1016\/j.rmr.2024.05.004_bib0030","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1016\/j.jtho.2023.06.017","article-title":"Genomic alterations and the incidence of brain metastases in advanced and metastatic NSCLC: a systematic review and meta-analysis","volume":"18","author":"Gillespie","year":"2023","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.rmr.2024.05.004_bib0035","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1093\/neuonc\/nox077","article-title":"Incidence and prognosis of patients with brain metastases at diagnosis of systemic malignancy: a population-based study","volume":"19","author":"Cagney","year":"2017","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.rmr.2024.05.004_bib0040","doi-asserted-by":"crossref","first-page":"e373","DOI":"10.1016\/j.cllc.2018.01.007","article-title":"Non-small-cell lung cancer with brain metastasis at presentation","volume":"19","author":"Waqar","year":"2018","journal-title":"Clin Lung Cancer"},{"key":"10.1016\/j.rmr.2024.05.004_bib0045","doi-asserted-by":"crossref","first-page":"e000024","DOI":"10.1136\/esmoopen-2015-000024","article-title":"Descriptive statistical analysis of a real life cohort of 2419\u00a0patients with brain metastases of solid cancers","volume":"1","author":"Berghoff","year":"2016","journal-title":"ESMO Open"},{"key":"10.1016\/j.rmr.2024.05.004_bib0050","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.ijrobp.2022.03.020","volume":"114","author":"Sperduto","year":"2022","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.rmr.2024.05.004_bib0055","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1001\/jamaoncol.2016.3834","article-title":"Estimating survival in patients with lung cancer and brain metastases: an update of the graded prognostic assessment for lung cancer using molecular markers (lung-molGPA)","volume":"3","author":"Sperduto","year":"2017","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.rmr.2024.05.004_bib0060","doi-asserted-by":"crossref","first-page":"3773","DOI":"10.1200\/JCO.20.01255","article-title":"Survival in patients with brain metastases: summary report on the updated diagnosis-specific graded prognostic assessment and definition of the eligibility quotient","volume":"38","author":"Sperduto","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.rmr.2024.05.004_bib0065","doi-asserted-by":"crossref","first-page":"iv192","DOI":"10.1093\/annonc\/mdy275","article-title":"Metastatic non-small cell lung cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"29","author":"Planchard","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1016\/j.rmr.2024.05.004_bib0070","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","article-title":"Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer","volume":"375","author":"Reck","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.rmr.2024.05.004_bib0075","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1056\/NEJMoa1801005","article-title":"Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer","volume":"378","author":"Gandhi","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.rmr.2024.05.004_bib0080","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1056\/NEJMoa1810865","article-title":"Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer","volume":"379","author":"Paz-Ares","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.rmr.2024.05.004_bib0085","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1158\/1078-0432.CCR-06-2854","article-title":"The blood-brain barrier and cancer: transporters, treatment, and Trojan horses","volume":"13","author":"Deeken","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.rmr.2024.05.004_bib0090","doi-asserted-by":"crossref","first-page":"4648","DOI":"10.18632\/oncotarget.27837","article-title":"Comparative genomic analysis of primary tumors and paired brain metastases in lung cancer patients by whole exome sequencing: a pilot study","volume":"11","author":"Tomasini","year":"2020","journal-title":"Oncotarget"},{"key":"10.1016\/j.rmr.2024.05.004_bib0095","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1158\/2159-8290.CD-15-0369","article-title":"Genomic characterization of brain metastases reveals branched evolution and potential therapeutic targets","volume":"5","author":"Brastianos","year":"2015","journal-title":"Cancer Discov"},{"key":"10.1016\/j.rmr.2024.05.004_bib0100","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1007\/s00262-016-1874-x","article-title":"Concepts in glioma immunotherapy","volume":"65","author":"Platten","year":"2016","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.rmr.2024.05.004_bib0105","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1056\/NEJMoa1507643","article-title":"Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer","volume":"373","author":"Borghaei","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.rmr.2024.05.004_bib0110","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1016\/S0140-6736(15)01281-7","article-title":"Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial","volume":"387","author":"Herbst","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.rmr.2024.05.004_bib0115","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/S0140-6736(16)32517-X","article-title":"Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial","volume":"389","author":"Rittmeyer","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.rmr.2024.05.004_bib0120","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1016\/S0140-6736(18)32409-7","article-title":"Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3\u00a0trial","volume":"393","author":"Mok","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.rmr.2024.05.004_bib0125","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1056\/NEJMoa1917346","article-title":"Atezolizumab for first-line treatment of PD-L1\u00a0\u2013\u00a0selected patients with NSCLC","volume":"383","author":"Herbst","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.rmr.2024.05.004_bib0130","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1016\/S0140-6736(21)00228-2","article-title":"Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1\u00a0of at least 50\u00a0%: a multicentre, open-label, global, phase 3, randomised, controlled trial","volume":"397","author":"Sezer","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.rmr.2024.05.004_bib0135","doi-asserted-by":"crossref","first-page":"2415","DOI":"10.1056\/NEJMoa1613493","article-title":"First-line nivolumab in stage IV or recurrent non-small-cell lung cancer","volume":"376","author":"Carbone","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.rmr.2024.05.004_bib0140","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1001\/jamaoncol.2020.0237","article-title":"Durvalumab with or without tremelimumab vs standard chemotherapy in first-line treatment of metastatic non-small cell lung cancer: the MYSTIC phase 3\u00a0randomized clinical trial","volume":"6","author":"Rizvi","year":"2020","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.rmr.2024.05.004_bib0145","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1056\/NEJMoa1910231","article-title":"Nivolumab plus ipilimumab in advanced non-small-cell lung cancer","volume":"381","author":"Hellmann","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.rmr.2024.05.004_bib0150","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1056\/NEJMoa1801946","article-title":"Nivolumab plus Ipilimumab in lung cancer with a high tumor mutational burden","volume":"378","author":"Hellmann","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.rmr.2024.05.004_bib0155","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/S1470-2045(20)30641-0","article-title":"First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3\u00a0trial","volume":"22","author":"Paz-Ares","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.rmr.2024.05.004_bib0160","doi-asserted-by":"crossref","first-page":"2288","DOI":"10.1056\/NEJMoa1716948","article-title":"Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC","volume":"378","author":"Socinski","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.rmr.2024.05.004_bib0165","doi-asserted-by":"crossref","first-page":"2872","DOI":"10.1200\/JCO.2018.79.0006","article-title":"Impact of baseline steroids on efficacy of programmed cell death-1\u00a0and programmed death-ligand 1\u00a0blockade in patients with non-small-cell lung cancer","volume":"36","author":"Arbour","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.rmr.2024.05.004_bib0170","doi-asserted-by":"crossref","first-page":"e100","DOI":"10.1097\/JTO.0000000000000587","article-title":"Central nervous system pseudoprogression in a patient treated with PD-1\u00a0checkpoint inhibitor","volume":"10","author":"Doherty","year":"2015","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.rmr.2024.05.004_bib0175","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1056\/NEJMoa1504627","article-title":"Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer","volume":"373","author":"Brahmer","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.rmr.2024.05.004_bib0180","first-page":"100205","article-title":"Outcomes with pembrolizumab monotherapy in patients with programmed death-ligand 1-positive NSCLC with brain metastases: pooled analysis of KEYNOTE-001, 010, 024, and 042","volume":"2","author":"Mansfield","year":"2021","journal-title":"JTO Clin Res Rep"},{"key":"10.1016\/j.rmr.2024.05.004_bib0185","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1016\/j.jtho.2021.06.020","article-title":"Outcomes with pembrolizumab plus platinum-based chemotherapy for patients with NSCLC and stable brain metastases: pooled analysis of KEYNOTE-021, -189, and -407","volume":"16","author":"Powell","year":"2021","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.rmr.2024.05.004_bib0190","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/S1470-2045(20)30111-X","article-title":"Pembrolizumab for management of patients with NSCLC and brain metastases: long-term results and biomarker analysis from a non-randomised, open-label, phase 2\u00a0trial","volume":"21","author":"Goldberg","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.rmr.2024.05.004_bib0195","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1016\/j.jtho.2023.01.083","article-title":"Efficacy, safety, and health-related quality of life with camrelizumab plus pemetrexed and carboplatin as first-line treatment for advanced nonsquamous NSCLC with brain metastases (CAP-BRAIN): a multicenter, open-label, single-arm, phase 2\u00a0study","volume":"18","author":"Hou","year":"2023","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.rmr.2024.05.004_bib0200","doi-asserted-by":"crossref","first-page":"4478","DOI":"10.1200\/JCO.22.02561","article-title":"Trial of atezolizumab combined with carboplatin and pemetrexed for patients with advanced nonsquamous non-small-cell lung cancer with untreated brain metastases (Atezo-Brain, GECP17\/05)","volume":"41","author":"Nadal","year":"2023","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.rmr.2024.05.004_bib316","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1016\/j.jtho.2019.02.009","article-title":"Outcome of Patients with Non-Small Cell Lung Cancer and Brain Metastases Treated with Checkpoint Inhibitors","volume":"14","author":"Hendriks","year":"2019","journal-title":"J Thorac Oncol"},{"issue":"7","key":"10.1016\/j.rmr.2024.05.004_bib317","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1080\/0284186X.2019.1615636","article-title":"Efficacy and safety of immune checkpoint inhibitors in a Danish real life non-small cell lung cancer population: a retrospective cohort study","volume":"58","author":"Bj\u00f8rnhart","year":"2019","journal-title":"Acta Oncol"},{"issue":"1","key":"10.1016\/j.rmr.2024.05.004_bib318","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.cllc.2020.10.017","article-title":"Outcomes in Patients With Non-small-cell Lung Cancer With Brain Metastases Treated With Pembrolizumab-based Therapy","volume":"22","author":"Sun","year":"2021","journal-title":"Clin Lung Cancer"},{"issue":"4","key":"10.1016\/j.rmr.2024.05.004_bib319","doi-asserted-by":"crossref","first-page":"656","DOI":"10.21037\/tlcr-22-260","article-title":"The clinical outcome and risk factors analysis of immune checkpoint inhibitor-based treatment in lung adenocarcinoma patients with brain metastases","volume":"11","author":"Zhou","year":"2022","journal-title":"Transl Lung Cancer Res"},{"key":"10.1016\/j.rmr.2024.05.004_bib320","doi-asserted-by":"crossref","first-page":"107321","DOI":"10.1016\/j.lungcan.2023.107321","article-title":"Impact of first- line immunotherapy on survival and intracranial outcomes in a cohort of non-small cell lung cancer patients with brain metastases at diagnosis","volume":"184","author":"Nigen","year":"2023","journal-title":"Lung Cancer"},{"key":"10.1016\/j.rmr.2024.05.004_bib321","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.lungcan.2016.05.031","article-title":"Intracranial response to nivolumab in NSCLC patients with untreated or progressing CNS metastases","volume":"98","author":"Dudnik","year":"2016","journal-title":"Lung Cancer"},{"issue":"4","key":"10.1016\/j.rmr.2024.05.004_bib322","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0195945","article-title":"Clinical factors associated with early progression and grade 3-4 toxicity in patients with advanced non-small- cell lung cancers treated with nivolumab","volume":"13","author":"Dumenil","year":"2018","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/j.rmr.2024.05.004_bib323","doi-asserted-by":"crossref","first-page":"e349","DOI":"10.1016\/j.cllc.2018.01.001","article-title":"Real-world Efficacy and Safety of Nivolumab for Advanced Non-Small-cell Lung Cancer: A Retrospective Multicenter Analysis","volume":"19","author":"Kobayashi","year":"2018","journal-title":"Clin Lung Cancer"},{"issue":"3","key":"10.1016\/j.rmr.2024.05.004_bib324","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1007\/s00262-019-02462-1","article-title":"Comparable outcomes of nivolumab in patients with advanced NSCLC presenting with or without brain metastases: a retrospective cohort study","volume":"69","author":"Zhang","year":"2020","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.rmr.2024.05.004_bib0205","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1016\/j.jtho.2021.04.014","article-title":"Immunotherapy as single treatment for patients with NSCLC with brain metastases: a systematic review and meta-analysis\u00a0\u2013\u00a0the META-L-BRAIN study","volume":"16","author":"Teixeira Loiola de Alencar","year":"2021","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.rmr.2024.05.004_bib0210","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/j.annonc.2022.02.008","article-title":"Effectiveness of PD-(L)1\u00a0inhibitors alone or in combination with platinum-doublet chemotherapy in first-line (1L) non-squamous non-small-cell lung cancer (Nsq-NSCLC) with PD-L1-high expression using real-world data","volume":"33","author":"P\u00e9rol","year":"2022","journal-title":"Ann Oncol"},{"key":"10.1016\/j.rmr.2024.05.004_bib0215","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1007\/s00262-022-03359-2","article-title":"Real-world multicentre cohort of first-line pembrolizumab alone or in combination with platinum-based chemotherapy in non-small cell lung cancer PD-L1\u00a0\u2265\u00a050","volume":"72","author":"Pons-Tostivint","year":"2023","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.rmr.2024.05.004_bib0220","doi-asserted-by":"crossref","first-page":"689","DOI":"10.21037\/tlcr-22-515","article-title":"Efficacy of different therapies for brain metastases of non-small cell lung cancer: a systematic review and meta-analysis","volume":"12","author":"Chen","year":"2023","journal-title":"Transl Lung Cancer Res"},{"key":"10.1016\/j.rmr.2024.05.004_bib0225","doi-asserted-by":"crossref","first-page":"236","DOI":"10.4103\/2152-7806.111301","article-title":"Whole brain radiotherapy for brain metastasis","volume":"4","author":"McTyre","year":"2013","journal-title":"Surg Neurol Int"},{"key":"10.1016\/j.rmr.2024.05.004_bib0230","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/S1470-2045(14)70061-0","article-title":"Stereotactic radiosurgery for patients with multiple brain metastases (JLGK0901): a multi-institutional prospective observational study","volume":"15","author":"Yamamoto","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.rmr.2024.05.004_bib0235","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1159\/000493056","article-title":"Stereotactic radiosurgery for patients with 10\u00a0or more brain metastases","volume":"34","author":"Yamamoto","year":"2019","journal-title":"Prog Neurol Surg"},{"key":"10.1016\/j.rmr.2024.05.004_bib0240","doi-asserted-by":"crossref","first-page":"336","DOI":"10.3389\/fonc.2018.00336","article-title":"Brain radiation necrosis: current management with a focus on non-small cell lung cancer patients","volume":"8","author":"Loganadane","year":"2018","journal-title":"Front Oncol"},{"key":"10.1016\/j.rmr.2024.05.004_bib0245","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1007\/s11060-012-0881-9","article-title":"does not reliably distinguish radiation necrosis from tumor recurrence after stereotactic radiosurgery","volume":"109","author":"Stockham","year":"2012","journal-title":"J Neurooncol"},{"key":"10.1016\/j.rmr.2024.05.004_bib0250","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1016\/j.ijrobp.2023.01.017","article-title":"Concurrent administration of immune checkpoint inhibitors and single fraction stereotactic radiosurgery in patients with non-small cell lung cancer, melanoma, and renal cell carcinoma brain metastases","volume":"116","author":"Lehrer","year":"2023","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.rmr.2024.05.004_bib0255","doi-asserted-by":"crossref","first-page":"2962","DOI":"10.1093\/annonc\/mdx408","article-title":"Combined irradiation and targeted therapy or immune checkpoint blockade in brain metastases: toxicities and efficacy","volume":"28","author":"Tallet","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.rmr.2024.05.004_bib0260","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1016\/j.ijrobp.2023.01.017","article-title":"Concurrent administration of immune checkpoint inhibitors and single fraction stereotactic radiosurgery in patients with non-small cell lung cancer, melanoma, and renal cell carcinoma brain metastases","volume":"116","author":"Lehrer","year":"2023","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.rmr.2024.05.004_bib0265","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/j.canrad.2012.07.179","article-title":"Stereotactic radiotherapy of intracranial benign tumors","volume":"16","author":"No\u00ebl","year":"2012","journal-title":"Cancer Radiother"},{"key":"10.1016\/j.rmr.2024.05.004_bib0270","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1007\/s11060-017-2437-5","article-title":"Outcomes targeting the PD-1\/PD-L1\u00a0axis in conjunction with stereotactic radiation for patients with non-small cell lung cancer brain metastases","volume":"133","author":"Ahmed","year":"2017","journal-title":"J Neurooncol"},{"key":"10.1016\/j.rmr.2024.05.004_bib0275","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1016\/j.ijrobp.2017.11.041","article-title":"Concurrent immune checkpoint inhibitors and stereotactic radiosurgery for brain metastases in non-small cell lung cancer, melanoma, and renal cell carcinoma","volume":"100","author":"Chen","year":"2018","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"4","key":"10.1016\/j.rmr.2024.05.004_bib0280","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/j.jtho.2018.01.012","article-title":"Safety of Combined PD-1 pathway inhibition and intracranial radiation therapy in non-small cell lung cancer","volume":"13","author":"Hubbeling","year":"2018","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.rmr.2024.05.004_bib0285","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1001\/jamaoncol.2017.3993","article-title":"Immunotherapy and symptomatic radiation necrosis in patients with brain metastases treated with stereotactic radiation","volume":"4","author":"Martin","year":"2018","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.rmr.2024.05.004_bib0290","doi-asserted-by":"crossref","first-page":"103431","DOI":"10.1016\/j.critrevonc.2021.103431","article-title":"Role of stereotactic radiosurgery for the treatment of brain metastasis in the era of immunotherapy: a systematic review on current evidences and predicting factors","volume":"165","author":"Gagliardi","year":"2021","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.rmr.2024.05.004_bib0295","first-page":"100655","article-title":"Immunotherapy with radiotherapy for brain metastases in patients with NSCLC: NEJ060","volume":"5","author":"Tozuka","year":"2024","journal-title":"JTO Clin Res Rep"},{"key":"10.1016\/j.rmr.2024.05.004_bib0300","first-page":"402","article-title":"Immunotherapy is associated with improved survival and decreased neurologic death after SRS for brain metastases from lung and melanoma primaries","volume":"6","author":"Lanier","year":"2019","journal-title":"Neurooncol Pract"},{"key":"10.1016\/j.rmr.2024.05.004_bib0305","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.cllc.2020.10.014","article-title":"Combined immunotherapy and stereotactic radiotherapy improves neurologic outcomes in patients with non-small-cell lung cancer brain metastases","volume":"22","author":"Enright","year":"2021","journal-title":"Clin Lung Cancer"},{"issue":"3","key":"10.1016\/j.rmr.2024.05.004_bib0310","doi-asserted-by":"crossref","first-page":"685","DOI":"10.3171\/2019.4.JNS19822","article-title":"Stereotactic radiosurgery with and without checkpoint inhibition for patients with metastatic non-small cell lung cancer to the brain: a matched cohort study","volume":"133","author":"Shepard","year":"2019","journal-title":"J Neurosurg"},{"key":"10.1016\/j.rmr.2024.05.004_bib0315","doi-asserted-by":"crossref","first-page":"512","DOI":"10.3171\/2018.10.JNS181371","article-title":"Local tumor response and survival outcomes after combined stereotactic radiosurgery and immunotherapy in non-small cell lung cancer with brain metastases","volume":"132","author":"Singh","year":"2019","journal-title":"J Neurosurg"}],"container-title":["Revue des Maladies Respiratoires"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0761842524002262?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0761842524002262?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,9,30]],"date-time":"2024-09-30T05:51:32Z","timestamp":1727675492000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0761842524002262"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10]]},"references-count":72,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["S0761842524002262"],"URL":"https:\/\/doi.org\/10.1016\/j.rmr.2024.05.004","relation":{},"ISSN":["0761-8425"],"issn-type":[{"type":"print","value":"0761-8425"}],"subject":[],"published":{"date-parts":[[2024,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"CBNPC sans addictions oncog\u00e9niques m\u00e9tastatique c\u00e9r\u00e9bral d\u2019embl\u00e9e\u00a0: place de l\u2019immunoth\u00e9rapie","name":"articletitle","label":"Article Title"},{"value":"Revue des Maladies Respiratoires","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rmr.2024.05.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 SPLF. Published by Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}